Search Results - "Damian, Doris"

Accelerated evolution of resistance in multidrug environments by Hegreness, Matthew, Shoresh, Noam, Damian, Doris, Hartl, Daniel, Kishony, Roy

“…The emergence of resistance during multidrug chemotherapy impedes the treatment of many human diseases, including malaria, TB, HIV, and cancer. Although…”
Get full text

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers by Stuve, Olaf, Soelberg Soerensen, Per, Leist, Thomas, Giovannoni, Gavin, Hyvert, Yann, Damian, Doris, Dangond, Fernando, Boschert, Ursula

“…Background: Cladribine tablets 3.5 mg/kg cumulative over 2 years (CT3.5) had significant clinical/imaging effects in patients with clinically isolated syndrome…”
Get full text

Multivariate classification analysis of metabolomic data for candidate biomarker discovery in type 2 diabetes mellitus by Qiu, Yang, Rajagopalan, Dilip, Connor, Susan C, Damian, Doris, Zhu, Lei, Handzel, Amir, Hu, Guanghui, Amanullah, Arshad, Bao, Steve, Woody, Nathaniel, MacLean, David, Lee, Kwan, Vanderwall, Dana, Ryan, Terence

“…Recent advances in genomics, metabolomics and proteomics have made it possible to interrogate disease pathophysiology and drug response on a systems level. The…”
Get full text

Variance modeling for nonstationary spatial processes with temporal replications by Damian, Doris, Sampson, Paul D., Guttorp, Peter

“…We have previously formulated a Bayesian approach to the Sampson and Guttorp model for the nonstationary correlation function r(x, x′) of a Gaussian spatial…”
Get full text

024  CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets by Vermersch, Patrick, Rammohan, Kottil, Damian, Doris, Jack, Dominic, Harty, Gerard, Wong, Schiffon

“…BackgroundCladribine tablets 10mg (cumulative dose 3.5mg/kg [CT3.5] over 2 years) showed efficacy vs placebo in patients with relapsing-remitting multiple…”
Get full text

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update by Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew

“…•We report on 272 cladribine tablets (CladT)-treated patients who acquired COVID-19.•Of the total evaluable cohort, 40 (15%) experienced serious…”
Get full text

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety by Giovannoni, Gavin, Galazka, Andrew, Schick, Regina, Leist, Thomas, Comi, Giancarlo, Montalban, Xavier, Damian, Doris, Dangond, Fernando, Cook, Stuart

“…Introduction Although use of contraception was pre-specified during cladribine clinical trials for multiple sclerosis, some pregnancies did occur. Objective…”
Get full text

Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections and COVID-19 (1927) by Giovannoni, Gavin, Berger, Joseph, Leist, Thomas, Jack, Dominic, Galazka, Andrew, Nolting, Axel, Damian, Doris

“…Abstract only…”
Get full text

022  Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data by Cook, Stuart, Giovannoni, Gavin, Leist, Thomas, Comi, Giancarlo, Syed, Sana, Nolting, Axel, Damian, Doris, Schick, Regina, Jack, Dominic

“…BackgroundThis analysis updates on the previously reported serious treatment emergent adverse event (TEAE) profile of cladribine tablets (CT) 10mg (cumulative…”
Get full text

Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data (1656) by Cook, Stuart, Giovannoni, Gavin, Leist, Thomas, Comi, Giancarlo, Syed, Sana, Nolting, Axel, Damian, Doris, Schick, Regina

“…Abstract only…”
Get full text

Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment by Vermersch, Patrick, Galazka, Andrew, Dangond, Fernando, Damian, Doris, Wong, Schiffon L., Jack, Dominic, Harty, Gerard

“…Relapsing-remitting multiple sclerosis (RRMS) patients with high disease activity (HDA) experience more severe disease than those without HDA. This analysis…”
Get full text

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease by Khanna, Dinesh, Tashkin, Donald P, Wells, Athol U, Seibold, James R, Wax, Stephen, Vazquez-Mateo, Cristina, Fleuranceau-Morel, Patricia, Damian, Doris, Denton, Christopher P

“…To investigate the effects of abituzumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD). STRATUS was a phase II, double-blind,…”
Get full text

Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial (P3.2-061) by Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Lebson, Lori, Leist, Thomas

“…Abstract only…”
Get full text

Updated safety analysis of cladribine tablets in the treatment of patients with multiple sclerosis (P4.2-046) by Cook, Stuart, Giovannoni, Gavin, Leist, Thomas, Syed, Sana, Nolting, Axel, Damian, Doris, Schick, Regina

“…Abstract only…”
Get full text

The effect of cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLE-MS study (P3.2-101) by Bowen, James, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Jones, Daniel, Grosso, Megan, Leist, Thomas

“…Abstract only…”
Get full text

088 Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial by Gillett, Alan, Scarberry, Susan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Lebson, Lori, Leist, Thomas

“…Introduction In ORACLE-MS (616 subjects with a first demyelinating event at high risk of converting to multiple sclerosis), cladribine tablets (CT) 10 mg (3.5…”
Get full text

090 The effect of cladribine tablets on delaying the time to conversion to clinically definite multiple sclerosis (MS) or McDonald MS is consistent across subgroups in the ORACLE-MS study by Bowen, James, Gillett, Alan, Damian, Doris, Hyvert, Yann, Dangond, Fernando, Grosso, Megan, Leist, Thomas

“…Introduction In the Phase 3 ORACLE-MS trial in 616 subjects with a first demyelinating event at high risk of converting to multiple sclerosis (MS), treatment…”
Get full text

An analysis of the relationship between cladribine dose and risk of malignancies in patients with multiple sclerosis (1928) by Cook, Stuart, Giovannoni, Gavin, Leist, Thomas, Comi, Giancarlo, Nolting, Axel, Sylvester, Elke, Jack, Dominic, Damian, Doris, Galazka, Andrew

“…Abstract only…”
Get full text

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update by Jack, Dominic, Damian, Doris, Nolting, Axel, Galazka, Andrew

“…The COVID-19 pandemic is a concern for people with multiple sclerosis (pwMS), especially those receiving disease-modifying therapies. We previously summarized…”
Get full text

WED 183 Cladribine tablets effects on t cell subsets in patients with early ms by Stuve, Olaf, Soelberg-Sorensen, Per, Leist, Thomas, Hyvert, Yann, Damian, Doris, Boschert, Ursula

“…BackgroundBecause of the durable clinical effects of cladribine tablets 3.5 mg/kg (CT3.5) in patients with multiple sclerosis, the influence of treatment on…”
Get full text